Artiva Biotherapeutics, Common Stock Today
| ARTV Stock | 10.40 0.22 2.07% |
Performance1 of 100
| Odds Of DistressLess than 28
|
Artiva Biotherapeutics, is selling for under 10.40 as of the 18th of December 2024; that is 2.07 percent decrease since the beginning of the trading day. The stock's lowest day price was 10.13. Artiva Biotherapeutics, has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 24th of December 2023 and ending today, the 18th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of July 2024 | Category Healthcare | Classification Health Care |
Artiva Biotherapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 24.29 M outstanding shares of which 1.03 M shares are presently shorted by private and institutional investors with about 20.47 trading days to cover. More on Artiva Biotherapeutics, Common
Moving against Artiva Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Artiva Stock Highlights
| CEO President | Fred MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Artiva Biotherapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Artiva Biotherapeutics,'s financial leverage. It provides some insight into what part of Artiva Biotherapeutics,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Artiva Biotherapeutics, Common (ARTV) is traded on NASDAQ Exchange in USA. It is located in 5505 Morehouse Drive, San Diego, CA, United States, 92121 and employs 82 people. Artiva Biotherapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 252.61 M. Artiva Biotherapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24.29 M outstanding shares of which 1.03 M shares are presently shorted by private and institutional investors with about 20.47 trading days to cover.
Artiva Biotherapeutics, generates negative cash flow from operations
Check Artiva Biotherapeutics, Probability Of Bankruptcy
Ownership AllocationArtiva Biotherapeutics, holds a total of 24.29 Million outstanding shares. The majority of Artiva Biotherapeutics, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Artiva Biotherapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Artiva Biotherapeutics,. Please pay attention to any change in the institutional holdings of Artiva Biotherapeutics, Common as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million three hundred fifty-one thousand two hundred four invesors are currently shorting Artiva Biotherapeutics, expressing very little confidence in its future performance.
Check Artiva Ownership Details
Artiva Biotherapeutics, Historical Income Statement
Artiva Stock Against Markets
Artiva Biotherapeutics, Corporate Management
| David Moriarty | Senior Operations | Profile | |
| Christopher Horan | Chief Officer | Profile | |
| Thorsten MD | Chief Officer | Profile | |
| Eugene Helsel | Senior Affairs | Profile |
Already Invested in Artiva Biotherapeutics, Common?
The danger of trading Artiva Biotherapeutics, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Artiva Biotherapeutics, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Artiva Biotherapeutics,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Artiva Biotherapeutics, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.